B-intervention	0	7	Aspirin
O	8	11	and
O	12	17	serum
O	18	27	estrogens
O	28	30	in
O	31	45	postmenopausal
O	46	51	women
O	51	52	:
O	53	54	a
O	55	65	randomized
O	66	76	controlled
O	77	85	clinical
O	86	91	trial
O	91	92	.

O	93	106	Epidemiologic
O	107	114	studies
O	115	122	suggest
O	123	124	a
O	125	132	reduced
O	133	137	risk
O	138	140	of
O	141	147	breast
O	148	154	cancer
O	155	160	among
O	161	166	women
O	167	170	who
O	171	174	use
O	175	182	aspirin
O	182	183	.

O	184	185	A
O	186	195	plausible
O	196	205	mechanism
O	206	208	is
O	209	216	through
O	217	224	aspirin
O	224	225	'
O	225	226	s
O	227	233	effect
O	234	236	on
O	237	246	estrogens
O	246	247	,
O	248	256	possibly
O	257	265	mediated
O	266	273	through
O	274	286	interference
O	287	291	with
O	292	300	estrogen
O	301	310	synthesis
O	311	314	via
O	315	324	reduction
O	325	327	in
O	328	340	inflammation
O	340	341	,
O	342	347	which
O	348	350	is
O	351	360	increased
O	361	363	in
O	364	371	adipose
O	372	379	tissues
O	379	380	,
O	381	390	including
O	391	397	breast
O	397	398	.

O	399	401	In
O	402	403	a
O	404	414	randomized
O	415	422	placebo
O	422	423	-
O	423	433	controlled
O	434	439	trial
O	439	440	,
O	441	443	we
O	444	453	evaluated
O	454	457	the
O	458	465	effects
O	466	468	of
O	469	472	six
O	472	473	-
O	473	478	month
O	479	493	administration
O	494	496	of
O	497	500	325
O	501	503	mg
O	503	504	/
O	504	507	day
O	508	515	aspirin
O	516	518	on
O	519	524	serum
O	525	534	estrogens
O	535	536	(
O	536	545	estradiol
O	545	546	,
O	547	554	estrone
O	554	555	,
O	556	560	free
O	561	570	estradiol
O	570	571	,
O	572	575	and
O	576	588	bioavailable
O	589	598	estradiol
O	598	599	)
O	600	603	and
O	604	607	sex
O	608	615	hormone
O	615	616	-
O	616	623	binding
O	624	632	globulin
O	633	634	(
O	634	638	SHBG
O	638	639	)
O	640	642	in
B-total-participants	643	646	144
B-eligibility	647	654	healthy
I-eligibility	655	669	postmenopausal
I-eligibility	670	675	women
O	675	676	.

O	677	685	Eligible
O	686	698	participants
O	698	699	,
O	700	709	recruited
O	710	714	2005
O	714	715	-
O	715	719	2007
O	719	720	,
O	721	725	were
O	726	729	not
O	730	736	taking
O	737	749	nonsteroidal
O	750	754	anti
O	754	755	-
O	755	767	inflammatory
O	768	778	medication
O	778	779	,
O	780	789	including
O	790	797	aspirin
O	798	799	>
O	799	800	2
O	801	806	times
O	806	807	/
O	807	811	week
O	812	814	or
O	815	825	menopausal
O	826	833	hormone
O	834	841	therapy
O	841	842	,
O	843	846	and
O	847	850	had
O	851	852	a
O	853	859	Breast
O	860	867	Imaging
O	867	868	-
O	868	877	Reporting
O	878	881	and
O	882	886	Data
O	887	893	System
O	894	895	(
O	895	897	BI
O	897	898	-
O	898	902	RADS
O	902	903	)
O	904	916	mammographic
O	917	924	density
O	925	939	classification
O	940	942	of
O	943	944	2
O	944	945	,
O	946	947	3
O	947	948	,
O	949	951	or
O	952	953	4
O	953	954	.

O	955	958	The
O	959	971	intervention
O	972	979	effects
O	980	981	(
O	981	987	intent
O	987	988	-
O	988	990	to
O	990	991	-
O	991	996	treat
O	996	997	)
O	998	1002	were
O	1003	1012	evaluated
O	1013	1015	by
O	1016	1027	differences
O	1028	1030	in
O	1031	1034	the
O	1035	1044	geometric
O	1045	1049	mean
O	1050	1057	outcome
O	1058	1065	changes
O	1066	1068	at
O	1069	1072	six
O	1073	1079	months
O	1080	1087	between
O	1088	1095	aspirin
O	1096	1099	and
B-control	1100	1107	placebo
I-control	1108	1114	groups
O	1115	1120	using
O	1121	1132	generalized
O	1133	1143	estimating
O	1144	1153	equations
O	1154	1155	(
O	1155	1158	GEE
O	1158	1159	)
O	1159	1160	.

O	1161	1173	Participants
O	1174	1178	were
O	1179	1180	a
O	1181	1185	mean
B-age	1186	1188	59
I-age	1188	1189	.
I-age	1189	1190	4
O	1191	1192	(
O	1192	1194	SD
O	1194	1195	,
O	1196	1197	5
O	1197	1198	.
O	1198	1199	4
O	1199	1200	)
O	1201	1206	years
O	1207	1209	of
O	1210	1213	age
O	1213	1214	,
O	1215	1219	with
O	1220	1221	a
O	1222	1226	mean
O	1227	1231	body
O	1232	1236	mass
O	1237	1242	index
O	1243	1244	(
O	1244	1247	BMI
O	1247	1248	)
O	1249	1251	of
O	1252	1254	26
O	1254	1255	.
O	1255	1256	4
O	1257	1258	(
O	1258	1260	SD
O	1260	1261	,
O	1262	1263	5
O	1263	1264	.
O	1264	1265	4
O	1265	1266	)
O	1267	1269	kg
O	1269	1270	/
O	1270	1271	m
O	1271	1272	(
O	1272	1273	2
O	1273	1274	)
O	1274	1275	.

O	1276	1283	Between
O	1284	1292	baseline
O	1293	1296	and
O	1297	1300	six
O	1301	1307	months
O	1307	1308	,
O	1309	1313	none
O	1314	1316	of
O	1317	1320	the
B-outcome	1321	1326	serum
I-outcome	1327	1336	estrogens
I-outcome	1337	1339	or
I-outcome	1340	1344	SHBG
O	1345	1352	changed
O	1353	1366	substantially
O	1367	1370	and
O	1371	1376	there
O	1377	1381	were
O	1382	1384	no
O	1385	1396	differences
O	1397	1404	between
O	1405	1411	groups
O	1411	1412	.

B-outcome	1413	1424	Stratifying
I-outcome	1425	1427	by
I-outcome	1428	1431	BMI
O	1432	1435	did
O	1436	1439	not
O	1440	1446	change
O	1447	1454	results
O	1454	1455	.

O	1456	1458	In
O	1459	1469	conclusion
O	1469	1470	,
O	1471	1472	a
O	1473	1479	single
O	1480	1485	daily
O	1486	1500	administration
O	1501	1503	of
O	1504	1507	325
O	1508	1510	mg
O	1511	1513	of
O	1514	1521	aspirin
O	1522	1525	for
O	1526	1529	six
O	1530	1536	months
O	1537	1540	had
O	1541	1543	no
O	1544	1550	effect
O	1551	1553	on
B-outcome	1554	1559	serum
I-outcome	1560	1569	estrogens
I-outcome	1570	1572	or
I-outcome	1573	1577	SHBG
O	1578	1580	in
O	1581	1595	postmenopausal
O	1596	1601	women
O	1601	1602	.

O	1603	1609	Larger
O	1610	1615	doses
O	1616	1618	or
O	1619	1625	longer
O	1626	1634	duration
O	1635	1637	of
O	1638	1645	aspirin
O	1646	1660	administration
O	1661	1664	may
O	1665	1667	be
O	1668	1674	needed
O	1675	1677	to
O	1678	1684	affect
O	1685	1696	circulating
O	1697	1706	estrogens
O	1706	1707	.

O	1708	1719	Alternately
O	1719	1720	,
O	1721	1723	if
O	1724	1731	aspirin
O	1732	1742	influences
O	1743	1749	breast
O	1750	1756	cancer
O	1757	1761	risk
O	1762	1764	in
O	1765	1779	postmenopausal
O	1780	1785	women
O	1785	1786	,
O	1787	1789	it
O	1790	1793	may
O	1794	1796	do
O	1797	1799	so
O	1800	1807	through
O	1808	1814	direct
O	1815	1821	breast
O	1822	1828	tissue
O	1829	1836	effects
O	1836	1837	,
O	1838	1840	or
O	1841	1848	through
O	1849	1857	pathways
O	1858	1863	other
O	1864	1868	than
O	1869	1878	estrogens
O	1878	1879	.
